vs
CHINA PHARMA HOLDINGS, INC.（CPHI）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
CHINA PHARMA HOLDINGS, INC.的季度营收约是Arcadia Biosciences, Inc.的1.4倍（$1.2M vs $901.0K），CHINA PHARMA HOLDINGS, INC.净利率更高（-99.7% vs -148.3%，领先48.6%），CHINA PHARMA HOLDINGS, INC.同比增速更快（8.1% vs -25.8%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -5.4%）
太阳药业是总部位于印度孟买的跨国制药企业，在全球逾100个国家生产销售药品制剂与原料药，是印度规模最大的制药企业，同时也是全球第四大特色仿制药企业。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
CPHI vs RKDA — 直观对比
营收规模更大
CPHI
是对方的1.4倍
$901.0K
营收增速更快
CPHI
高出34.0%
-25.8%
净利率更高
CPHI
高出48.6%
-148.3%
两年增速更快
RKDA
近两年复合增速
-5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $901.0K |
| 净利润 | $-1.2M | $-1.3M |
| 毛利率 | 12.3% | 21.4% |
| 营业利润率 | -97.9% | -152.8% |
| 净利率 | -99.7% | -148.3% |
| 营收同比 | 8.1% | -25.8% |
| 净利润同比 | 0.2% | 67.1% |
| 每股收益（稀释后） | $-0.17 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPHIRKDA
| Q4 25 | $1.2M | $901.0K | ||
| Q3 25 | $756.2K | $1.3M | ||
| Q2 25 | $1.0M | $1.5M | ||
| Q1 25 | $1.1M | $1.2M | ||
| Q4 24 | $1.1M | $1.2M | ||
| Q3 24 | $1.1M | $1.5M | ||
| Q2 24 | $924.9K | $1.3M | ||
| Q1 24 | $1.4M | $987.0K |
净利润CPHIRKDA
| Q4 25 | $-1.2M | $-1.3M | ||
| Q3 25 | $-651.5K | $856.0K | ||
| Q2 25 | $-528.4K | $-4.5M | ||
| Q1 25 | $-785.6K | $2.6M | ||
| Q4 24 | $-1.2M | $-4.1M | ||
| Q3 24 | $-1.1M | $-1.6M | ||
| Q2 24 | $-1.4M | $1.1M | ||
| Q1 24 | $-955.9K | $-2.4M |
毛利率CPHIRKDA
| Q4 25 | 12.3% | 21.4% | ||
| Q3 25 | -7.9% | 32.1% | ||
| Q2 25 | -8.5% | 43.4% | ||
| Q1 25 | -12.0% | 43.2% | ||
| Q4 24 | -14.2% | 31.9% | ||
| Q3 24 | -47.2% | 32.9% | ||
| Q2 24 | -109.8% | 51.5% | ||
| Q1 24 | -21.2% | 52.3% |
营业利润率CPHIRKDA
| Q4 25 | -97.9% | -152.8% | ||
| Q3 25 | -83.1% | -88.5% | ||
| Q2 25 | -63.6% | -34.4% | ||
| Q1 25 | -66.8% | 44.2% | ||
| Q4 24 | -105.5% | -187.7% | ||
| Q3 24 | -98.6% | -114.5% | ||
| Q2 24 | -150.4% | — | ||
| Q1 24 | -66.9% | -160.9% |
净利率CPHIRKDA
| Q4 25 | -99.7% | -148.3% | ||
| Q3 25 | -86.2% | 65.7% | ||
| Q2 25 | -51.5% | -306.4% | ||
| Q1 25 | -69.1% | 216.6% | ||
| Q4 24 | -108.0% | -334.5% | ||
| Q3 24 | -101.6% | -104.9% | ||
| Q2 24 | -155.5% | 81.2% | ||
| Q1 24 | -69.8% | -245.5% |
每股收益（稀释后）CPHIRKDA
| Q4 25 | $-0.17 | $-0.97 | ||
| Q3 25 | $-0.17 | $0.62 | ||
| Q2 25 | $-0.16 | $-3.26 | ||
| Q1 25 | $-0.24 | $1.90 | ||
| Q4 24 | $-0.45 | $-2.99 | ||
| Q3 24 | $-0.65 | $-1.18 | ||
| Q2 24 | $-0.89 | $0.78 | ||
| Q1 24 | $-0.72 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $345.1K | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $22.7M | $4.1M |
| 总资产 | $31.0M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPHIRKDA
| Q4 25 | $345.1K | $4.6M | ||
| Q3 25 | $267.6K | $5.9M | ||
| Q2 25 | $600.0K | $4.4M | ||
| Q1 25 | $400.0K | $3.2M | ||
| Q4 24 | $626.9K | $4.2M | ||
| Q3 24 | $700.0K | $6.6M | ||
| Q2 24 | — | $8.1M | ||
| Q1 24 | — | $8.5M |
股东权益CPHIRKDA
| Q4 25 | $22.7M | $4.1M | ||
| Q3 25 | $8.3M | $5.4M | ||
| Q2 25 | $6.5M | $4.5M | ||
| Q1 25 | $7.0M | $8.9M | ||
| Q4 24 | $7.7M | $6.2M | ||
| Q3 24 | $6.5M | $10.3M | ||
| Q2 24 | $7.4M | $11.7M | ||
| Q1 24 | $8.3M | $10.6M |
总资产CPHIRKDA
| Q4 25 | $31.0M | $6.5M | ||
| Q3 25 | $15.8M | $8.6M | ||
| Q2 25 | $13.8M | $7.8M | ||
| Q1 25 | $14.2M | $13.0M | ||
| Q4 24 | $14.9M | $13.5M | ||
| Q3 24 | $13.5M | $15.2M | ||
| Q2 24 | $14.3M | $17.4M | ||
| Q1 24 | — | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.0K | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | $151.5K | — |
| 自由现金流率自由现金流/营收 | 12.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $88.8K | — |
8季度趋势，按日历期对齐
经营现金流CPHIRKDA
| Q4 25 | $152.0K | $-861.0K | ||
| Q3 25 | $-237.0K | $-257.0K | ||
| Q2 25 | $291.1K | $-2.0M | ||
| Q1 25 | $-57.8K | $-1.6M | ||
| Q4 24 | $298.8K | $-2.2M | ||
| Q3 24 | $-47.0K | $-1.8M | ||
| Q2 24 | $-72.7K | $-2.5M | ||
| Q1 24 | $-585.2K | $-3.2M |
自由现金流CPHIRKDA
| Q4 25 | $151.5K | — | ||
| Q3 25 | $-237.6K | — | ||
| Q2 25 | $291.0K | — | ||
| Q1 25 | $-116.1K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.2K | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率CPHIRKDA
| Q4 25 | 12.4% | — | ||
| Q3 25 | -31.4% | — | ||
| Q2 25 | 28.4% | — | ||
| Q1 25 | -10.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.1% | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度CPHIRKDA
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 5.1% | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.8% | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率CPHIRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
